{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:27:07Z","timestamp":1789090027600,"version":"build-2803163510"},"reference-count":380,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vaginal Cancer outline the recommended diagnostic workup, staging considerations, and treatment options for this rare malignancy. Because vaginal cancer is uncommon and shares many biologic and clinical characteristics with cervical cancer, several management recommendations, particularly systemic therapy, are extrapolated from evidence and practices established for cervical cancer. This guideline excerpt summarizes key components of management, including diagnostic evaluation and workup, principles of staging, pathology considerations, radiation therapy principles, and primary treatment recommendations for both early-stage and advanced disease. It also details approaches to manage relapses, including locoregional recurrence and distant metastases, and provides an in-depth overview of systemic therapy recommendations for vaginal cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0011","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:30Z","timestamp":1770644790000},"page":"101-126","source":"Crossref","is-referenced-by-count":2,"title":["Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Amarnath","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Arend","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barber","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bradley","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Brooks","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Chino","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Ann","family":"Crispens","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Damast","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Fisher","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Frederick","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gaillard","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Giuntoli","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Glaser","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Landrum","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Lee","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mantia-Smaldone","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutch","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Nagel","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Nekhlyudov","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Nwachukwu","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Podoll","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Rodabaugh","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schorge","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Schuetze","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soliman","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Ueda","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Urban","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wyse","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"McMillian","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Sambandam","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Crit Rev Oncol Hematol","first-page":"286","article-title":"Vaginal cancer","volume":"81","author":"Di Donato V","year":"2012","unstructured":"Di Donato V, Bellati F, Fischetti M,  Vaginal cancer. Crit Rev Oncol Hematol 2012;81:286\u2013295."},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B3","series-title":"Gynecol Oncol","first-page":"501","article-title":"Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis","volume":"150","author":"Matsuo K","year":"2018","unstructured":"Matsuo K, Blake EA, Machida H,  Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecol Oncol 2018;150:501\u2013508."},{"key":"B4","series-title":"BJOG","first-page":"448","article-title":"Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study","volume":"127","author":"Alfonzo E","year":"2020","unstructured":"Alfonzo E, Holmberg E, Spar\u00e9n P,  Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. BJOG 2020;127:448\u2013454."},{"key":"B5","series-title":"PLoS One","first-page":"e88323","article-title":"Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance","volume":"9","author":"Nygard M","year":"2014","unstructured":"Nygard M, Hansen BT, Dillner J,  Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 2014;9:e88323."},{"key":"B6","series-title":"Obstet Gynecol Clin North Am","first-page":"213","article-title":"Vulvar and vaginal cancer","volume":"39","author":"Carter JS","year":"2012","unstructured":"Carter JS, Downs LS. Vulvar and vaginal cancer. Obstet Gynecol Clin North Am 2012;39:213\u2013231."},{"key":"B7","series-title":"Front Oncol","first-page":"883805","article-title":"A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention","volume":"12","author":"Baral SK","year":"2022","unstructured":"Baral SK, Biswas P, Kaium MA,  A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention. Front Oncol 2022;12:883805."},{"key":"B8","series-title":"J Clin Oncol","first-page":"2975","article-title":"Impact of the human papilloma vaccine on cervical cancer","volume":"25","author":"Chan JK","year":"2007","unstructured":"Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975\u20132982."},{"key":"B9","series-title":"Expert Rev Anticancer Ther","first-page":"29","article-title":"Immunosuppression and risk of cervical cancer","volume":"13","author":"Dugue PA","year":"2013","unstructured":"Dugue PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther 2013;13:29\u201342."},{"key":"B10","series-title":"PDQ Cancer Information Summaries","article-title":"Cervical cancer causes, risk factors, and prevention","year":"2002","unstructured":"National Cancer Institute. Cervical cancer causes, risk factors, and prevention. In: PDQ Cancer Information Summaries. Bethesda, MD: National Cancer Institute (US); 2002."},{"key":"B11","series-title":"Geburtshilfe Frauenheilkd","first-page":"1145","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"Hohn AK","year":"2021","unstructured":"Hohn AK, Brambs CE, Hiller GGR,  2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 2021;81:1145\u20131153."},{"key":"B12","series-title":"Int J Gynaecol Obstet","first-page":"3","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","year":"2009","unstructured":"FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009;105:3\u20134."},{"key":"B13","article-title":"Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Uterine Cervix","author":"Krishnamurti U","unstructured":"Krishnamurti U, Movahedi-Lankarani S, Bell DA,  Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Uterine Cervix. Accessed December 11, 2025. Available at: https:\/\/documents.cap.org\/protocols\/cp-femalereproductive-uterinecervix-resection-20-4300.pdf"},{"key":"B14","series-title":"J Low Genit Tract Dis","first-page":"205","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"16","author":"Darragh TM","year":"2012","unstructured":"Darragh TM, Colgan TJ, Cox JT,  The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205\u2013242."},{"key":"B15","series-title":"J Low Genit Tract Dis","first-page":"131","article-title":"The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia","volume":"27","author":"Kesic V","year":"2023","unstructured":"Kesic V, Carcopino X, Preti M,  The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. J Low Genit Tract Dis 2023;27:131\u2013145."},{"key":"B16","series-title":"N Engl J Med","first-page":"1856","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo N","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D,  Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021;385:1856\u20131867."},{"key":"B17","series-title":"J Clin Oncol","first-page":"1470","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung HC","year":"2019","unstructured":"Chung HC, Ros W, Delord JP,  Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:1470\u20131478."},{"key":"B18","series-title":"J Clin Oncol","first-page":"2825","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann RW","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T,  Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial. J Clin Oncol 2019;37:2825\u20132834."},{"key":"B19","series-title":"J Obstet Gynaecol Res","first-page":"2010","article-title":"Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: a case enrolled in the BELIEVE trial","volume":"48","author":"Yoshimoto D","year":"2022","unstructured":"Yoshimoto D, Taguchi A, Tanikawa M,  Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: a case enrolled in the BELIEVE trial. J Obstet Gynaecol Res 2022;48:2010\u20132014."},{"key":"B20","series-title":"Gynecol Oncol","first-page":"161","article-title":"Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002)","volume":"157","author":"Santin AD","year":"2020","unstructured":"Santin AD, Deng W, Frumovitz M,  Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002). Gynecol Oncol 2020;157:161\u2013166."},{"key":"B21","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA,  Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.  J Clin Oncol 2020;38:1\u201310."},{"key":"B22","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B23","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L,  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B24","series-title":"Clin Cancer Res","first-page":"1302","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion- positive solid tumors","volume":"28","author":"Demetri GD","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A,  Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion- positive solid tumors. Clin Cancer Res 2022;28:1302\u20131312."},{"key":"B25","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B26","series-title":"Lancet Oncol","first-page":"531","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S,  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 2020;21:531\u2013540."},{"key":"B27","series-title":"Clin Cancer Res","first-page":"928","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus L","year":"2021","unstructured":"Marcus L, Donoghue M, Aungst S,  FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res 2021;27:928\u2013932."},{"key":"B28","series-title":"Drugs","first-page":"201","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott LJ.","year":"2019","unstructured":"Scott LJ. Larotrectinib: first global approval. Drugs 2019;79:201\u2013206."},{"key":"B29","series-title":"Ann Oncol","first-page":"S787","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon BJ","year":"2023","unstructured":"Solomon BJ, Drilon A, Lin JJ,  1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial. Ann Oncol 2023;34:S787\u2013788."},{"key":"B30","article-title":"FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion- positive solid tumors","unstructured":"Food and Drug Administration. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion- positive solid tumors. Accessed January 24, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive"},{"key":"B31","series-title":"Cancer Metastasis Rev","first-page":"157","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan M","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D,  HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015;34:157\u2013164."},{"key":"B32","series-title":"BMC Cancer","first-page":"59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco A","year":"2004","unstructured":"Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A,  HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59."},{"key":"B33","series-title":"PLoS One","first-page":"e0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta- analysis","volume":"16","author":"Itkin B","year":"2021","unstructured":"Itkin B, Garcia A, Straminsky S,  Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta- analysis. PLoS One 2021;16:e0257976."},{"key":"B34","series-title":"Am J Cancer Res","first-page":"3266","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials","volume":"13","author":"Cai ZL","year":"2023","unstructured":"Cai ZL, Yang HT, Huang T,  Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials. Am J Cancer Res 2023;13:3266\u20133274."},{"key":"B35","series-title":"J Clin Oncol","first-page":"47","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A,  Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42:47\u201358."},{"key":"B36","series-title":"Lancet Oncol","first-page":"1261","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B,  Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 2022;23:1261\u20131273."},{"key":"B37","series-title":"Clin Cancer Res","first-page":"3573","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke ES","year":"2023","unstructured":"Duke ES, Bradford D, Marcovitz M,  FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res 2023;29:3573\u20133578."},{"key":"B38","series-title":"Br J Cancer","first-page":"1561","article-title":"Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina","volume":"110","author":"Hellman K","year":"2014","unstructured":"Hellman K, Lindquist D, Ranhem C,  Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina. Br J Cancer 2014;110:1561\u20131570."},{"key":"B39","series-title":"Am J Clin Pathol","first-page":"664","article-title":"Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1","volume":"142","author":"Feldbaum VM","year":"2014","unstructured":"Feldbaum VM, Flowers LC, Oprea-Ilies GM. Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. Am J Clin Pathol 2014;142:664\u2013669."},{"key":"B40","series-title":"Cancers (Basel)","first-page":"1046","article-title":"The role of P16, P53, KI-67 and PD-L1 immunostaining in primary vaginal cancer","volume":"15","author":"Egger EK","year":"2023","unstructured":"Egger EK, Condic M, Ralser DJ,  The role of P16, P53, KI-67 and PD-L1 immunostaining in primary vaginal cancer. Cancers (Basel) 2023;15:1046."},{"key":"B41","series-title":"Acta Obstet Gynecol Scand","first-page":"2144","article-title":"The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: a systematic review","volume":"100","author":"Rasmussen CL","year":"2021","unstructured":"Rasmussen CL, Bertoli HK, Sand FL,  The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: a systematic review. Acta Obstet Gynecol Scand 2021;100:2144\u20132156."},{"key":"B42","series-title":"Gynecol Oncol","first-page":"649","article-title":"Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes","volume":"159","author":"Kortekaas KE","year":"2020","unstructured":"Kortekaas KE, Bastiaannet E, van Doorn HC,  Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol 2020;159:649\u2013656."},{"key":"B43","series-title":"J Low Genit Tract Dis","first-page":"252","article-title":"Biomarkers p16, human papillomavirus and p53 predict recurrence and survival in early stage squamous cell carcinoma of the vulva","volume":"20","author":"Hay CM","year":"2016","unstructured":"Hay CM, Lachance JA, Lucas FL,  Biomarkers p16, human papillomavirus and p53 predict recurrence and survival in early stage squamous cell carcinoma of the vulva. J Low Genit Tract Dis 2016;20:252\u2013256."},{"key":"B44","series-title":"Anticancer Res","first-page":"1739","article-title":"P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus","volume":"25","author":"Hantschmann P","year":"2005","unstructured":"Hantschmann P, Sterzer S, Jeschke U, Friese K. P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus. Anticancer Res 2005;25:1739\u20131745."},{"key":"B45","series-title":"Gynecol Oncol","first-page":"547","article-title":"A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas","volume":"90","author":"Koyamatsu Y","year":"2003","unstructured":"Koyamatsu Y, Yokoyama M, Nakao Y,  A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. Gynecol Oncol 2003;90:547\u2013551."},{"key":"B46","series-title":"Int J Radiat Oncol Biol Phys","first-page":"746","article-title":"Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum","volume":"69","author":"Samant R","year":"2007","unstructured":"Samant R, Lau B, E C,  Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 2007;69:746\u2013750."},{"key":"B47","series-title":"Gynecol Oncol","first-page":"233","article-title":"Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract","volume":"43","author":"Roberts WS","year":"1991","unstructured":"Roberts WS, Hoffman MS, Kavanagh JJ,  Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract. Gynecol Oncol 1991;43:233\u2013236."},{"key":"B48","series-title":"Gynecol Oncol","first-page":"3","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani R","year":"2017","unstructured":"Salani R, Khanna N, Frimer M,  An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:3\u201310."},{"key":"B49","series-title":"J Am Coll Radiol","first-page":"S442","article-title":"ACR Appropriateness Criteria\u00ae Staging and Follow-up of Primary Vaginal Cancer","volume":"18","author":"Kilcoyne A","year":"2021","unstructured":"Kilcoyne A, Gottumukkala RV, Kang SK,  ACR Appropriateness Criteria\u00ae Staging and Follow-up of Primary Vaginal Cancer. J Am Coll Radiol 2021;18:S442\u2013455."},{"key":"B50","series-title":"Gynecol Oncol","first-page":"187","article-title":"Posttherapy surveillance of women with cervical cancer: an outcomes analysis","volume":"78","author":"Bodurka-Bevers D","year":"2000","unstructured":"Bodurka-Bevers D, Morris M, Eifel PJ,  Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:187\u2013193."},{"key":"B51","series-title":"Ann Oncol","first-page":"218","article-title":"Value of routine follow-up procedures for patients with stage I\/II cervical cancer treated with combined surgery-radiation therapy","volume":"15","author":"Morice P","year":"2004","unstructured":"Morice P, Deyrolle C, Rey A,  Value of routine follow-up procedures for patients with stage I\/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004;15:218\u2013223."},{"key":"B52","series-title":"Gynecol Oncol","first-page":"528","article-title":"Follow-up for women after treatment for cervical cancer: a systematic review","volume":"114","author":"Elit L","year":"2009","unstructured":"Elit L, Fyles AW, Devries MC,  Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009;114:528\u2013535."},{"key":"B53","series-title":"Gynecol Oncol","first-page":"529","article-title":"Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence","volume":"104","author":"Chung HH","year":"2007","unstructured":"Chung HH, Jo H, Kang WJ,  Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529\u2013534."},{"key":"B54","series-title":"J Clin Oncol","first-page":"967","article-title":"Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix","volume":"27","author":"Chaturvedi AK","year":"2009","unstructured":"Chaturvedi AK, Kleinerman RA, Hildesheim A,  Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009;27:967\u2013973."},{"key":"B55","series-title":"J Natl Cancer Inst","first-page":"1634","article-title":"Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk","volume":"99","author":"Chaturvedi AK","year":"2007","unstructured":"Chaturvedi AK, Engels EA, Gilbert ES,  Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634\u20131643."},{"key":"B56","series-title":"Obstet Gynecol","first-page":"319","article-title":"Radiation-associated endometrial cancer","volume":"113","author":"Kumar S","year":"2009","unstructured":"Kumar S, Shah JP, Bryant CS,  Radiation-associated endometrial cancer. Obstet Gynecol 2009;113:319\u2013325."},{"key":"B57","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1247","article-title":"Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix","volume":"55","author":"Kim JS","year":"2003","unstructured":"Kim JS, Kim JS, Kim SY,  Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2003;55:1247\u20131253."},{"key":"B58","series-title":"Gynecol Oncol","first-page":"126","article-title":"Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I\/II study","volume":"97","author":"Chung YL","year":"2005","unstructured":"Chung YL, Jian JJ, Cheng SH,  Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I\/II study. Gynecol Oncol 2005;97:126\u2013135."},{"key":"B59","series-title":"Int J Gynecol Cancer","first-page":"974","article-title":"Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers","volume":"19","author":"Marnitz S","year":"2009","unstructured":"Marnitz S, Dowdy S, Lanowska M,  Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers. Int J Gynecol Cancer 2009;19:974\u2013977."},{"key":"B60","series-title":"Gynecol Oncol","first-page":"153","article-title":"Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA","volume":"99","author":"Berek JS","year":"2005","unstructured":"Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005;99:153\u2013159."},{"key":"B61","series-title":"Gynecol Oncol","first-page":"261","article-title":"Total pelvic exenteration: the Albert Einstein College of Medicine\/Montefiore Medical Center Experience (1987 to 2003)","volume":"101","author":"Goldberg GL","year":"2006","unstructured":"Goldberg GL, Sukumvanich P, Einstein MH,  Total pelvic exenteration: the Albert Einstein College of Medicine\/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 2006;101:261\u2013268."},{"key":"B62","series-title":"Obstet Gynecol","first-page":"934","article-title":"Pelvic exenteration, University of Michigan: 100 patients at 5 years","volume":"74","author":"Morley GW","year":"1989","unstructured":"Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989;74:934\u2013943."},{"key":"B63","series-title":"J Surg Oncol","first-page":"476","article-title":"Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers","volume":"95","author":"Fleisch MC","year":"2007","unstructured":"Fleisch MC, Pantke P, Beckmann MW,  Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 2007;95:476\u2013484."},{"key":"B64","series-title":"Int J Radiat Oncol Biol Phys","first-page":"504","article-title":"Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies","volume":"69","author":"Tran PT","year":"2007","unstructured":"Tran PT, Su Z, Hara W,  Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2007;69:504\u2013511."},{"key":"B65","series-title":"Am J Obstet Gynecol","first-page":"881","article-title":"Pelvic exenteration: analysis of 296 patients","volume":"129","author":"Rutledge FN","year":"1977","unstructured":"Rutledge FN, Smith JP, Wharton JT, O\u2019Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977;129:881\u2013892."},{"key":"B66","series-title":"Am J Obstet Gynecol","first-page":"907","article-title":"Exenterative operations: experience with 198 patients","volume":"121","author":"Symmonds RE","year":"1975","unstructured":"Symmonds RE, Pratt JH, Webb MJ. Exenterative operations: experience with 198 patients. Am J Obstet Gynecol 1975;121:907\u2013918."},{"key":"B67","series-title":"Int J Gynecol Cancer","first-page":"298","article-title":"Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity","volume":"17","author":"Soper JT","year":"2007","unstructured":"Soper JT, Secord AA, Havrilesky LJ,  Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity. Int J Gynecol Cancer 2007;17:298\u2013303."},{"key":"B68","series-title":"Gynecol Oncol","first-page":"39","article-title":"Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques","volume":"87","author":"Mirhashemi R","year":"2002","unstructured":"Mirhashemi R, Averette HE, Lambrou N,  Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques. Gynecol Oncol 2002;87:39\u201345."},{"key":"B69","series-title":"J Surg Oncol","first-page":"224","article-title":"Psychosocial issues: pelvic exenterative surgery","volume":"76","author":"Turns D.","year":"2001","unstructured":"Turns D. Psychosocial issues: pelvic exenterative surgery. J Surg Oncol 2001;76:224\u2013236."},{"key":"B70","series-title":"Radiat Oncol","first-page":"77","article-title":"Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients","volume":"10","author":"Im JH","year":"2015","unstructured":"Im JH, Yoon HI, Kim S,  Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients. Radiat Oncol 2015;10:77."},{"key":"B71","series-title":"Int J Gynecol Cancer","first-page":"1214","article-title":"Loop electrosurgical excision procedure findings for identification of patients with early-stage cervical cancer suitable for less radical surgery","volume":"22","author":"Kim MK","year":"2012","unstructured":"Kim MK, Kim MA, Kim JW,  Loop electrosurgical excision procedure findings for identification of patients with early-stage cervical cancer suitable for less radical surgery. Int J Gynecol Cancer 2012;22:1214\u20131219."},{"key":"B72","series-title":"J Palliat Med","first-page":"438","article-title":"Top ten tips palliative care clinicians should know about caring for patients with cervical cancer","volume":"24","author":"Hoppenot C","year":"2021","unstructured":"Hoppenot C, Littell RD, DeEulis T, Hartenbach EM. Top ten tips palliative care clinicians should know about caring for patients with cervical cancer. J Palliat Med 2021;24:438\u2013442."},{"key":"B73","series-title":"Best Pract Res Clin Obstet Gynaecol","first-page":"265","article-title":"Palliative radiation therapy for gynaecological malignancies","volume":"15","author":"Smith SC","year":"2001","unstructured":"Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol 2001;15:265\u2013278."},{"key":"B74","series-title":"Int J Radiat Oncol Biol Phys","first-page":"399","article-title":"Effect of rest interval on tumor and normal tissue response\u2013a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502)","volume":"25","author":"Spanos WJ","year":"1993","unstructured":"Spanos WJ, Perez CA, Marcus S,  Effect of rest interval on tumor and normal tissue response\u2013a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys 1993;25:399\u2013403."},{"key":"B75","series-title":"Cancer","first-page":"1462","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz ST","year":"2007","unstructured":"Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2007;109:1462\u20131470."},{"key":"B76","series-title":"J Clin Oncol","first-page":"2804","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Rose PG","year":"2007","unstructured":"Rose PG, Ali S, Watkins E,  Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2804\u20132810."},{"key":"B77","series-title":"Gynecol Oncol","first-page":"27","article-title":"Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence","volume":"93","author":"Viswanathan AN","year":"2004","unstructured":"Viswanathan AN, Deavers MT, Jhingran A,  Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004;93:27\u201333."},{"key":"B78","series-title":"Am J Obstet Gynecol","first-page":"503.e1","article-title":"Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial","volume":"197","author":"Stehman FB","year":"2007","unstructured":"Stehman FB, Ali S, Keys HM,  Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 2007;197:503.e1\u20136."},{"key":"B79","series-title":"Oncologist","first-page":"843","article-title":"Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks","volume":"18","author":"Nam EJ","year":"2013","unstructured":"Nam EJ, Lee M, Yim GW,  Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013;18:843\u2013849."},{"key":"B80","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1226","article-title":"Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial","volume":"55","author":"Lorvidhaya V","year":"2003","unstructured":"Lorvidhaya V, Chitapanarux I, Sangruchi S,  Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226\u20131232."},{"key":"B81","series-title":"Gynecol Oncol","first-page":"404","article-title":"Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma","volume":"81","author":"Pattaranutaporn P","year":"2001","unstructured":"Pattaranutaporn P, Thirapakawong C, Chansilpa Y,  Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001;81:404\u2013407."},{"key":"B82","series-title":"Radiat Oncol","first-page":"15","article-title":"Radiosensitizers in cervical cancer. Cisplatin and beyond","volume":"1","author":"Candelaria M","year":"2006","unstructured":"Candelaria M, Garcia-Arias A, Cetina L, Due\u00f1as-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15."},{"key":"B83","series-title":"Radiother Oncol","first-page":"181","article-title":"Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer","volume":"37","author":"Christie DR","year":"1995","unstructured":"Christie DR, Bull CA, Gebski V, Langlands AO. Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Radiother Oncol 1995;37:181\u2013189."},{"key":"B84","series-title":"Int J Radiat Oncol Biol Phys","first-page":"979","article-title":"Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix","volume":"38","author":"Rakovitch E","year":"1997","unstructured":"Rakovitch E, Fyles AW, Pintilie M, Leung PM. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:979\u2013987."},{"key":"B85","series-title":"J Gynecol Oncol","first-page":"221","article-title":"Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study","volume":"20","author":"Verma AK","year":"2009","unstructured":"Verma AK, Arya AK, Kumar M,  Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study. J Gynecol Oncol 2009;20:221\u2013226."},{"key":"B86","series-title":"Eur J Gynaecol Oncol","first-page":"115","article-title":"Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose","volume":"23","author":"Cerrotta A","year":"2002","unstructured":"Cerrotta A, Gardan G, Cavina R,  Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002;23:115\u2013119."},{"key":"B87","series-title":"J Clin Oncol","first-page":"5802","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802\u20135812."},{"key":"B88","series-title":"Clin Oncol (R Coll Radiol)","first-page":"38","article-title":"Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects","volume":"18","author":"King M","year":"2006","unstructured":"King M, McConkey C, Latief TN,  Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 2006;18:38\u201345."},{"key":"B89","series-title":"Clin Oncol (R Coll Radiol)","first-page":"358","article-title":"Long-term survival and late toxicity after chemoradiotherapy for cervical cancer\u2013the Addenbrooke's experience","volume":"20","author":"Tan LT","year":"2008","unstructured":"Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer\u2013the Addenbrooke's experience. Clin Oncol (R Coll Radiol) 2008;20:358\u2013364."},{"key":"B90","series-title":"J Clin Oncol","first-page":"5505","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk BJ","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS,  First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol 2023;41:5505\u20135511."},{"key":"B91","series-title":"Lancet","first-page":"1654","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari KS","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT,  Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654\u20131663."},{"key":"B92","series-title":"Lancet Oncol","first-page":"301","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson RT","year":"2015","unstructured":"Penson RT, Huang HQ, Wenzel LB,  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16:301\u2013311."},{"key":"B93","series-title":"Int J Gynecol Cancer","first-page":"1237","article-title":"Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer","volume":"27","author":"Rosen VM","year":"2017","unstructured":"Rosen VM, Guerra I, McCormack M,  Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 2017;27:1237\u20131246."},{"key":"B94","series-title":"J Clin Oncol","first-page":"2129","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa R","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T,  Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:2129\u20132135."},{"key":"B95","series-title":"Gynecol Oncol","first-page":"299","article-title":"A comparison of cisplatin\/paclitaxel and carboplatin\/paclitaxel in stage IVB, recurrent or persistent cervical cancer","volume":"105","author":"Moore KN","year":"2007","unstructured":"Moore KN, Herzog TJ, Lewin S,  A comparison of cisplatin\/paclitaxel and carboplatin\/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105:299\u2013303."},{"key":"B96","series-title":"Gynecol Oncol","first-page":"117","article-title":"A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer","volume":"133","author":"Lorusso D","year":"2014","unstructured":"Lorusso D, Petrelli F, Coinu A,  A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 2014;133:117\u2013123."},{"key":"B97","series-title":"Cancer","first-page":"899","article-title":"Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"48","author":"Thigpen T","year":"1981","unstructured":"Thigpen T, Shingleton H, Homesley H,  Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899\u2013903."},{"key":"B98","series-title":"Gynecol Oncol","first-page":"198","article-title":"A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"32","author":"Thigpen JT","year":"1989","unstructured":"Thigpen JT, Blessing JA, DiSaia PJ,  A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198\u2013202."},{"key":"B99","series-title":"Cancer Treat Rev","first-page":"603","article-title":"Chemotherapy for recurrent cervical cancer","volume":"34","author":"Pectasides D","year":"2008","unstructured":"Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008;34:603\u2013613."},{"key":"B100","series-title":"J Clin Oncol","first-page":"3113","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore DH","year":"2004","unstructured":"Moore DH, Blessing JA, McQuellon RP,  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113\u20133119."},{"key":"B101","series-title":"J Clin Oncol","first-page":"1462","article-title":"A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"7","author":"McGuire WP","year":"1989","unstructured":"McGuire WP, Arseneau J, Blessing JA,  A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462\u20131468."},{"key":"B102","series-title":"Gynecol Oncol","first-page":"332","article-title":"A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study","volume":"39","author":"Weiss GR","year":"1990","unstructured":"Weiss GR, Green S, Hannigan EV,  A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990;39:332\u2013336."},{"key":"B103","series-title":"Anticancer Drugs","first-page":"657","article-title":"An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix","volume":"8","author":"Kudelka AP","year":"1997","unstructured":"Kudelka AP, Winn R, Edwards CL,  An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997;8:657\u2013661."},{"key":"B104","series-title":"J Clin Oncol","first-page":"792","article-title":"Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study","volume":"14","author":"McGuire WP","year":"1996","unstructured":"McGuire WP, Blessing JA, Moore D,  Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996;14:792\u2013795."},{"key":"B105","series-title":"Gynecol Oncol","first-page":"54","article-title":"Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience","volume":"98","author":"Tinker AV","year":"2005","unstructured":"Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 2005;98:54\u201358."},{"key":"B106","series-title":"J Clin Oncol","first-page":"4626","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long HJ","year":"2005","unstructured":"Long HJ, Bundy BN, Grendys EC,  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626\u20134633."},{"key":"B107","series-title":"J Natl Compr Canc Netw","first-page":"53","article-title":"Chemotherapy for advanced, recurrent, and metastatic cervical cancer","volume":"6","author":"Moore DH.","year":"2008","unstructured":"Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008;6:53\u201357."},{"key":"B108","series-title":"Gynecol Oncol","first-page":"S67","article-title":"Chemotherapy for recurrent and metastatic cervical cancer","volume":"110","author":"Tao X","year":"2008","unstructured":"Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008;110:S67\u201371."},{"key":"B109","series-title":"J Clin Oncol","first-page":"4649","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk BJ","year":"2009","unstructured":"Monk BJ, Sill MW, McMeekin DS,  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649\u20134655."},{"key":"B110","series-title":"Gynecol Oncol","first-page":"64","article-title":"Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer","volume":"130","author":"Zighelboim I","year":"2013","unstructured":"Zighelboim I, Wright JD, Gao F,  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130:64\u201368."},{"key":"B111","series-title":"J Clin Oncol","first-page":"4035","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel JS","year":"2017","unstructured":"Frenel JS, Le Tourneau C, O\u2019Neil B,  Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 2017;35:4035\u20134041."},{"key":"B112","series-title":"Ann Oncol","first-page":"929","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio M","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L,  Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929\u2013938."},{"key":"B113","article-title":"FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection","unstructured":"Food and Drug Administration. FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection. Accessed November 10, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection"},{"key":"B114","series-title":"Gynecol Oncol","first-page":"451","article-title":"Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study","volume":"127","author":"Alberts DS","year":"2012","unstructured":"Alberts DS, Blessing JA, Landrum LM,  Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 2012;127:451\u2013455."},{"key":"B115","series-title":"Am J Clin Oncol","first-page":"428","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"30","author":"Garcia AA","year":"2007","unstructured":"Garcia AA, Blessing JA, Vaccarello L,  Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;30:428\u2013431."},{"key":"B116","series-title":"Am J Clin Oncol","first-page":"439","article-title":"A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"19","author":"Look KY","year":"1996","unstructured":"Look KY, Blessing JA, Gallup DG, Lentz SS. A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1996;19:439\u2013441."},{"key":"B117","series-title":"Gynecol Oncol","first-page":"103","article-title":"Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"96","author":"Schilder RJ","year":"2005","unstructured":"Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2005;96:103\u2013107."},{"key":"B118","series-title":"Cancer Chemother Pharmacol","first-page":"280","article-title":"A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix","volume":"18","author":"Coleman RE","year":"1986","unstructured":"Coleman RE, Harper PG, Gallagher C,  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986;18:280\u2013283."},{"key":"B119","series-title":"Am J Obstet Gynecol","first-page":"805","article-title":"Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study","volume":"168","author":"Sutton GP","year":"1993","unstructured":"Sutton GP, Blessing JA, McGuire WP,  Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993;168:805\u2013807."},{"key":"B120","series-title":"J Clin Oncol","first-page":"625","article-title":"Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix","volume":"15","author":"Verschraegen CF","year":"1997","unstructured":"Verschraegen CF, Levy T, Kudelka AP,  Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625\u2013631."},{"key":"B121","series-title":"Eur J Cancer","first-page":"1624","article-title":"Phase II study of mitomycin- C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study","volume":"37","author":"Wagenaar HC","year":"2001","unstructured":"Wagenaar HC, Pecorelli S, Mangioni C,  Phase II study of mitomycin- C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer 2001;37:1624\u20131628."},{"key":"B122","series-title":"Gynecol Oncol","first-page":"65","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller DS","year":"2008","unstructured":"Miller DS, Blessing JA, Bodurka DC,  Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110:65\u201370."},{"key":"B123","series-title":"Gynecol Oncol","first-page":"446","article-title":"Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"77","author":"Bookman MA","year":"2000","unstructured":"Bookman MA, Blessing JA, Hanjani P,  Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446\u2013449."},{"key":"B124","series-title":"Gynecol Oncol","first-page":"213","article-title":"A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"81","author":"Muderspach LI","year":"2001","unstructured":"Muderspach LI, Blessing JA, Levenback C, Moore JL. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001;81:213\u2013215."},{"key":"B125","series-title":"Gynecol Oncol","first-page":"108","article-title":"Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"96","author":"Muggia FM","year":"2005","unstructured":"Muggia FM, Blessing JA, Waggoner S,  Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:108\u2013111."},{"key":"B126","series-title":"Lancet Oncol","first-page":"609","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman RL","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C,  Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:609\u2013619."},{"key":"B127","series-title":"Drugs","first-page":"2141","article-title":"Tisotumab vedotin: first Approval","volume":"81","author":"Markham A.","year":"2021","unstructured":"Markham A. Tisotumab vedotin: first Approval. Drugs 2021;81:2141\u20132147."},{"key":"B128","series-title":"N Engl J Med","first-page":"44","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote I","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K,  Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 2024;391:44\u201355."},{"key":"B129","series-title":"N Engl J Med","first-page":"544","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari KS","year":"2022","unstructured":"Tewari KS, Monk BJ, Vergote I,  Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544\u2013555."},{"key":"B130","series-title":"Eur J Cancer","first-page":"299","article-title":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","volume":"174","author":"Oaknin A","year":"2022","unstructured":"Oaknin A, Monk BJ, Vergote I,  EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer 2022;174:299\u2013309."},{"key":"B131","series-title":"Lancet Oncol","first-page":"588","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial","volume":"25","author":"Oaknin A","year":"2024","unstructured":"Oaknin A, Moore K, Meyer T,  Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Lancet Oncol 2024;25:588\u2013602."},{"key":"B132","article-title":"FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection","unstructured":"Food and Drug Administration. FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection. Accessed January 24, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection"},{"key":"B133","series-title":"Oncology (Williston Park)","first-page":"1166","article-title":"ACR Appropriateness Criteria management of vaginal cancer","volume":"27","author":"Lee LJ","year":"2013","unstructured":"Lee LJ, Jhingran A, Kidd E,  ACR Appropriateness Criteria management of vaginal cancer. Oncology (Williston Park) 2013;27:1166\u20131173."},{"key":"B134","series-title":"Front Oncol","first-page":"34","article-title":"The role of PET\/CT in cervical cancer","volume":"3","author":"Herrera FG","year":"2013","unstructured":"Herrera FG, Prior JO. The role of PET\/CT in cervical cancer. Front Oncol 2013;3:34."},{"key":"B135","series-title":"Int J Radiat Oncol Biol Phys","first-page":"138","article-title":"Definitive radiation therapy for squamous cell carcinoma of the vagina","volume":"62","author":"Frank SJ","year":"2005","unstructured":"Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005;62:138\u2013147."},{"key":"B136","series-title":"Gynecol Oncol","first-page":"404","article-title":"Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology","volume":"120","author":"Higginson DS","year":"2011","unstructured":"Higginson DS, Morris DE, Jones EL,  Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol Oncol 2011;120:404\u2013412."},{"key":"B137","series-title":"Int J Radiat Oncol Biol Phys","first-page":"147","article-title":"Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer","volume":"74","author":"Choi CW","year":"2009","unstructured":"Choi CW, Cho CK, Yoo SY,  Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009;74:147\u2013153."},{"key":"B138","series-title":"Radiother Oncol","first-page":"36","article-title":"Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer","volume":"145","author":"Schmid MP","year":"2020","unstructured":"Schmid MP, Fokdal L, Westerveld H,  Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiother Oncol 2020;145:36\u201344."},{"key":"B139","series-title":"Int J Radiat Oncol Biol Phys","first-page":"654","article-title":"GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina","volume":"115","author":"Kamrava M","year":"2023","unstructured":"Kamrava M, Leung E, Bachand F,  GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina. Int J Radiat Oncol Biol Phys 2023;115:654\u2013663."},{"key":"B140","series-title":"Lancet Oncol","first-page":"538","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"Potter R","year":"2021","unstructured":"Potter R, Tanderup K, Schmid MP,  MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021;22:538\u2013547."},{"key":"B141","series-title":"Radiother Oncol","first-page":"24","article-title":"Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study","volume":"157","author":"Petric P","year":"2021","unstructured":"Petric P, Lindegaard JC, Sturdza A,  Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. Radiother Oncol 2021;157:24\u201331."},{"key":"B142","series-title":"Radiother Oncol","first-page":"116","article-title":"Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"Potter R","year":"2011","unstructured":"Potter R, Georg P, Dimopoulos JC,  Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 2011;100:116\u2013123."},{"key":"B143","series-title":"Radiother Oncol","first-page":"235","article-title":"Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-Meder C","year":"2005","unstructured":"Haie-Meder C, Potter R, Van Limbergen E,  Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005;74:235\u2013245."},{"key":"B144","series-title":"Int J Radiat Oncol Biol Phys","first-page":"788","article-title":"Assessment of parametrial response by growth pattern in patients with International Federation of Gynecology and Obstetrics stage IIB and IIIB cervical cancer: analysis of patients from a prospective, multicenter trial (EMBRACE)","volume":"93","author":"Yoshida K","year":"2015","unstructured":"Yoshida K, Jastaniyah N, Sturdza A,  Assessment of parametrial response by growth pattern in patients with International Federation of Gynecology and Obstetrics stage IIB and IIIB cervical cancer: analysis of patients from a prospective, multicenter trial (EMBRACE). Int J Radiat Oncol Biol Phys 2015;93:788\u2013796."},{"key":"B145","series-title":"Int J Radiat Oncol Biol Phys","first-page":"104","article-title":"Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society","volume":"76","author":"Viswanathan AN","year":"2010","unstructured":"Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2010;76:104\u2013109."},{"key":"B146","series-title":"Pract Radiat Oncol","first-page":"173","article-title":"An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: a single institution experience","volume":"1","author":"Hallock A","year":"2011","unstructured":"Hallock A, Surry K, Batchelar D,  An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: a single institution experience. Pract Radiat Oncol 2011;1:173\u2013181."},{"key":"B147","series-title":"Gynecol Oncol","first-page":"501","article-title":"Brachytherapy improves survival in primary vaginal cancer","volume":"141","author":"Orton A","year":"2016","unstructured":"Orton A, Boothe D, Williams N,  Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol 2016;141:501\u2013506."},{"key":"B148","series-title":"Acta Obstet Gynecol Scand","first-page":"355","article-title":"Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy","volume":"80","author":"Kucera H","year":"2001","unstructured":"Kucera H, Mock U, Knocke TH,  Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. Acta Obstet Gynecol Scand 2001;80:355\u2013360."},{"key":"B149","series-title":"Int J Radiat Oncol Biol Phys","first-page":"639","article-title":"Dosimetric considerations in irradiation of carcinoma of the vagina","volume":"2","author":"Perez CA","year":"1977","unstructured":"Perez CA, Korba A, Sharma S. Dosimetric considerations in irradiation of carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1977;2:639\u2013649."},{"key":"B150","series-title":"Brachytherapy","first-page":"68","article-title":"American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer","volume":"11","author":"Beriwal S","year":"2012","unstructured":"Beriwal S, Demanes DJ, Erickson B,  American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy 2012;11:68\u201375."},{"key":"B151","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1880","article-title":"Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results","volume":"82","author":"Dimopoulos JC","year":"2012","unstructured":"Dimopoulos JC, Schmid MP, Fidarova E,  Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 2012;82:1880\u20131888."},{"key":"B152","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1108","article-title":"Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series","volume":"62","author":"Ferrigno R","year":"2005","unstructured":"Ferrigno R, Nishimoto IN, Novaes PE,  Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series. Int J Radiat Oncol Biol Phys 2005;62:1108\u20131116."},{"key":"B153","series-title":"Clin Transl Radiat Oncol","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"Potter R","year":"2018","unstructured":"Potter R, Tanderup K, Kirisits C,  The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018;9:48\u201360."},{"key":"B154","series-title":"Gynecol Oncol","first-page":"456","article-title":"Management and outcomes of primary vaginal cancer","volume":"159","author":"Yang J","year":"2020","unstructured":"Yang J, Delara R, Magrina J,  Management and outcomes of primary vaginal cancer. Gynecol Oncol 2020;159:456\u2013463."},{"key":"B155","series-title":"Int J Radiat Oncol Biol Phys","first-page":"348","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer","volume":"79","author":"Lim K","year":"2011","unstructured":"Lim K, Small W, Portelance L,  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2011;79:348\u2013355."},{"key":"B156","series-title":"J Natl Compr Canc Netw","first-page":"1425","article-title":"The emerging use of IMRT for treatment of cervical cancer","volume":"8","author":"Loiselle C","year":"2010","unstructured":"Loiselle C, Koh WJ. The emerging use of IMRT for treatment of cervical cancer. J Natl Compr Canc Netw 2010;8:1425\u20131434."},{"key":"B157","series-title":"Int J Radiat Oncol Biol Phys","first-page":"166","article-title":"Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer","volume":"68","author":"Beriwal S","year":"2007","unstructured":"Beriwal S, Gan GN, Heron DE,  Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2007;68:166\u2013171."},{"key":"B158","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1438","article-title":"Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy","volume":"67","author":"Chen MF","year":"2007","unstructured":"Chen MF, Tseng CJ, Tseng CC,  Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1438\u20131444."},{"key":"B159","series-title":"Cancer J","first-page":"200","article-title":"Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients","volume":"14","author":"Chen MF","year":"2008","unstructured":"Chen MF, Tseng CJ, Tseng CC,  Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients. Cancer J 2008;14:200\u2013206."},{"key":"B160","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1170","article-title":"Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies","volume":"65","author":"Salama JK","year":"2006","unstructured":"Salama JK, Mundt AJ, Roeske J, Mehta N. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65:1170\u20131176."},{"key":"B161","series-title":"Int J Radiat Oncol Biol Phys","first-page":"428","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer","volume":"71","author":"Small W","year":"2008","unstructured":"Small W, Mell LK, Anderson P,  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:428\u2013434."},{"key":"B162","series-title":"Eur J Gynaecol Oncol","first-page":"62","article-title":"Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study","volume":"35","author":"Erpolat OP","year":"2014","unstructured":"Erpolat OP, Alco G, Caglar HB,  Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. Eur J Gynaecol Oncol 2014;35:62\u201366."},{"key":"B163","series-title":"Int J Radiat Oncol Biol Phys","first-page":"357","article-title":"Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer","volume":"88","author":"Verma J","year":"2014","unstructured":"Verma J, Sulman EP, Jhingran A,  Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 2014;88:357\u2013362."},{"key":"B164","series-title":"Int J Radiat Oncol Biol Phys","first-page":"536","article-title":"Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2)","volume":"97","author":"Mell LK","year":"2017","unstructured":"Mell LK, Sirak I, Wei L,  Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys 2017;97:536\u2013545."},{"key":"B165","series-title":"Radiother Oncol","first-page":"273","article-title":"The effect of treatment duration in the local control of cervix cancer","volume":"25","author":"Fyles A","year":"1992","unstructured":"Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25:273\u2013279."},{"key":"B166","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1051","article-title":"Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome","volume":"27","author":"Girinsky T","year":"1993","unstructured":"Girinsky T, Rey A, Roche B,  Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051\u20131056."},{"key":"B167","series-title":"Int J Radiat Oncol Biol Phys","first-page":"391","article-title":"The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study","volume":"25","author":"Lanciano RM","year":"1993","unstructured":"Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391\u2013397."},{"key":"B168","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1275","article-title":"Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy","volume":"32","author":"Perez CA","year":"1995","unstructured":"Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275\u20131288."},{"key":"B169","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1301","article-title":"The adverse effect of treatment prolongation in cervical carcinoma","volume":"32","author":"Petereit DG","year":"1995","unstructured":"Petereit DG, Sarkaria JN, Chappell R,  The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301\u20131307."},{"key":"B170","series-title":"Front Oncol","first-page":"943703","article-title":"Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: a single institution experience","volume":"12","author":"Ren X","year":"2022","unstructured":"Ren X, Fu Y, Liu Z,  Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: a single institution experience. Front Oncol 2022;12:943703."},{"key":"B171","series-title":"Clin Oncol (R Coll Radiol)","first-page":"682","article-title":"Stereotactic body reirradiation in gynaecological cancer: outcomes and toxicities from a single institution experience","volume":"35","author":"Macchia G","year":"2023","unstructured":"Macchia G, Pezzulla D, Cilla S,  Stereotactic body reirradiation in gynaecological cancer: outcomes and toxicities from a single institution experience. Clin Oncol (R Coll Radiol) 2023;35:682\u2013693."},{"key":"B172","series-title":"Gynecol Oncol","first-page":"208","article-title":"Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer","volume":"151","author":"Kim HJ","year":"2018","unstructured":"Kim HJ, Chang JS, Koom WS,  Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. Gynecol Oncol 2018;151:208\u2013214."},{"key":"B173","series-title":"PLoS One","first-page":"e65048","article-title":"Concurrent chemoradiation for vaginal cancer","volume":"8","author":"Miyamoto DT","year":"2013","unstructured":"Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. PLoS One 2013;8:e65048."},{"key":"B174","series-title":"Gynecol Oncol","first-page":"495","article-title":"Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study","volume":"135","author":"Rajagopalan MS","year":"2014","unstructured":"Rajagopalan MS, Xu KM, Lin JF,  Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol 2014;135:495\u2013502."},{"key":"B175","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1304","article-title":"Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients","volume":"73","author":"Wo JY","year":"2009","unstructured":"Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009;73:1304\u20131312."},{"key":"B176","series-title":"Int J Gynecol Cancer","first-page":"584","article-title":"Laparoscopic ovarian transposition in patients with early cervical cancer","volume":"18","author":"Pahisa J","year":"2008","unstructured":"Pahisa J, Martinez-Roman S, Martinez-Zamora MA,  Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer 2008;18:584\u2013589."},{"key":"B177","series-title":"Fertil Steril","first-page":"743","article-title":"Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination","volume":"74","author":"Morice P","year":"2000","unstructured":"Morice P, Juncker L, Rey A,  Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril 2000;74:743\u2013748."},{"key":"B178","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1289","article-title":"Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix","volume":"32","author":"Eifel PJ","year":"1995","unstructured":"Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995;32:1289\u20131300."},{"key":"B179","series-title":"Int J Gynecol Cancer","first-page":"1074","article-title":"Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix","volume":"20","author":"Forrest JL","year":"2010","unstructured":"Forrest JL, Ackerman I, Barbera L,  Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix. Int J Gynecol Cancer 2010;20:1074\u20131078."},{"key":"B180","first-page":"325","article-title":"Biologic and physical aspects of radiation oncology","author":"Erickson-Whitmann B","year":"2009","unstructured":"Erickson-Whitmann B, Rownd J, Khater K. Biologic and physical aspects of radiation oncology. In: Barakat R, Markman M, Randall M, eds. Principles and Practice of Gynecology Oncology, 5th Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:325\u2013380."},{"key":"B181","series-title":"Int J Radiat Oncol Biol Phys","first-page":"855","article-title":"Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation","volume":"44","author":"Perez CA","year":"1999","unstructured":"Perez CA, Grigsby PW, Lockett MA,  Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys 1999;44:855\u2013866."},{"key":"B182","series-title":"J Allergy Clin Immunol","first-page":"574","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells MC","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE,  Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574\u2013580."},{"key":"B183","series-title":"Ann Emerg Med","first-page":"373","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson HA","year":"2006","unstructured":"Sampson HA, Munoz-Furlong A, Campbell RL,  Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373\u2013380."},{"key":"B184","series-title":"Int J Emerg Med","first-page":"3","article-title":"Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis","volume":"2","author":"Manivannan V","year":"2009","unstructured":"Manivannan V, Decker WW, Stead LG,  Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:3\u20135."},{"key":"B185","series-title":"Oncologist","first-page":"601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz HJ.","year":"2007","unstructured":"Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601\u2013609."},{"key":"B186","series-title":"J Clin Oncol","first-page":"4611","article-title":"Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity","volume":"21","author":"Markman M","year":"2003","unstructured":"Markman M, Zanotti K, Peterson G,  Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611\u20134614."},{"key":"B187","series-title":"Gynecol Oncol","first-page":"393","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee CW","year":"2005","unstructured":"Lee CW, Matulonis UA, Castells MC. Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393\u2013399."},{"key":"B188","series-title":"Gynecol Oncol","first-page":"370","article-title":"Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions","volume":"95","author":"Lee CW","year":"2004","unstructured":"Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions. Gynecol Oncol 2004;95:370\u2013376."},{"key":"B189","series-title":"J Clin Virol","first-page":"189","article-title":"Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening","volume":"38","author":"Arbyn M","year":"2007","unstructured":"Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38:189\u2013197."},{"key":"B190","series-title":"CMAJ","first-page":"469","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials","volume":"177","author":"Rambout L","year":"2007","unstructured":"Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469\u2013479."},{"key":"B1","series-title":"Crit Rev Oncol Hematol","first-page":"286","article-title":"Vaginal cancer","volume":"81","author":"Di Donato V","year":"2012","unstructured":"Di Donato V, Bellati F, Fischetti M,  Vaginal cancer. Crit Rev Oncol Hematol 2012;81:286\u2013295."},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B3","series-title":"Gynecol Oncol","first-page":"501","article-title":"Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis","volume":"150","author":"Matsuo K","year":"2018","unstructured":"Matsuo K, Blake EA, Machida H,  Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecol Oncol 2018;150:501\u2013508."},{"key":"B4","series-title":"BJOG","first-page":"448","article-title":"Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study","volume":"127","author":"Alfonzo E","year":"2020","unstructured":"Alfonzo E, Holmberg E, Spar\u00e9n P,  Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. BJOG 2020;127:448\u2013454."},{"key":"B5","series-title":"PLoS One","first-page":"e88323","article-title":"Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance","volume":"9","author":"Nygard M","year":"2014","unstructured":"Nygard M, Hansen BT, Dillner J,  Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 2014;9:e88323."},{"key":"B6","series-title":"Obstet Gynecol Clin North Am","first-page":"213","article-title":"Vulvar and vaginal cancer","volume":"39","author":"Carter JS","year":"2012","unstructured":"Carter JS, Downs LS. Vulvar and vaginal cancer. Obstet Gynecol Clin North Am 2012;39:213\u2013231."},{"key":"B7","series-title":"Front Oncol","first-page":"883805","article-title":"A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention","volume":"12","author":"Baral SK","year":"2022","unstructured":"Baral SK, Biswas P, Kaium MA,  A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention. Front Oncol 2022;12:883805."},{"key":"B8","series-title":"J Clin Oncol","first-page":"2975","article-title":"Impact of the human papilloma vaccine on cervical cancer","volume":"25","author":"Chan JK","year":"2007","unstructured":"Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975\u20132982."},{"key":"B9","series-title":"Expert Rev Anticancer Ther","first-page":"29","article-title":"Immunosuppression and risk of cervical cancer","volume":"13","author":"Dugue PA","year":"2013","unstructured":"Dugue PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther 2013;13:29\u201342."},{"key":"B10","series-title":"PDQ Cancer Information Summaries","article-title":"Cervical cancer causes, risk factors, and prevention","year":"2002","unstructured":"National Cancer Institute. Cervical cancer causes, risk factors, and prevention. In: PDQ Cancer Information Summaries. Bethesda, MD: National Cancer Institute (US); 2002."},{"key":"B11","series-title":"Geburtshilfe Frauenheilkd","first-page":"1145","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"Hohn AK","year":"2021","unstructured":"Hohn AK, Brambs CE, Hiller GGR,  2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 2021;81:1145\u20131153."},{"key":"B12","series-title":"Int J Gynaecol Obstet","first-page":"3","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","year":"2009","unstructured":"FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009;105:3\u20134."},{"key":"B13","article-title":"Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Uterine Cervix","author":"Krishnamurti U","unstructured":"Krishnamurti U, Movahedi-Lankarani S, Bell DA,  Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Uterine Cervix. Accessed December 11, 2025. Available at: https:\/\/documents.cap.org\/protocols\/cp-femalereproductive-uterinecervix-resection-20-4300.pdf"},{"key":"B14","series-title":"J Low Genit Tract Dis","first-page":"205","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"16","author":"Darragh TM","year":"2012","unstructured":"Darragh TM, Colgan TJ, Cox JT,  The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205\u2013242."},{"key":"B15","series-title":"J Low Genit Tract Dis","first-page":"131","article-title":"The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia","volume":"27","author":"Kesic V","year":"2023","unstructured":"Kesic V, Carcopino X, Preti M,  The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. J Low Genit Tract Dis 2023;27:131\u2013145."},{"key":"B16","series-title":"N Engl J Med","first-page":"1856","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo N","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D,  Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021;385:1856\u20131867."},{"key":"B17","series-title":"J Clin Oncol","first-page":"1470","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung HC","year":"2019","unstructured":"Chung HC, Ros W, Delord JP,  Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:1470\u20131478."},{"key":"B18","series-title":"J Clin Oncol","first-page":"2825","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann RW","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T,  Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial. J Clin Oncol 2019;37:2825\u20132834."},{"key":"B19","series-title":"J Obstet Gynaecol Res","first-page":"2010","article-title":"Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: a case enrolled in the BELIEVE trial","volume":"48","author":"Yoshimoto D","year":"2022","unstructured":"Yoshimoto D, Taguchi A, Tanikawa M,  Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: a case enrolled in the BELIEVE trial. J Obstet Gynaecol Res 2022;48:2010\u20132014."},{"key":"B20","series-title":"Gynecol Oncol","first-page":"161","article-title":"Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002)","volume":"157","author":"Santin AD","year":"2020","unstructured":"Santin AD, Deng W, Frumovitz M,  Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002). Gynecol Oncol 2020;157:161\u2013166."},{"key":"B21","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA,  Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.  J Clin Oncol 2020;38:1\u201310."},{"key":"B22","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B23","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L,  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B24","series-title":"Clin Cancer Res","first-page":"1302","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion- positive solid tumors","volume":"28","author":"Demetri GD","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A,  Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion- positive solid tumors. Clin Cancer Res 2022;28:1302\u20131312."},{"key":"B25","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B26","series-title":"Lancet Oncol","first-page":"531","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S,  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 2020;21:531\u2013540."},{"key":"B27","series-title":"Clin Cancer Res","first-page":"928","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus L","year":"2021","unstructured":"Marcus L, Donoghue M, Aungst S,  FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res 2021;27:928\u2013932."},{"key":"B28","series-title":"Drugs","first-page":"201","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott LJ.","year":"2019","unstructured":"Scott LJ. Larotrectinib: first global approval. Drugs 2019;79:201\u2013206."},{"key":"B29","series-title":"Ann Oncol","first-page":"S787","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon BJ","year":"2023","unstructured":"Solomon BJ, Drilon A, Lin JJ,  1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial. Ann Oncol 2023;34:S787\u2013788."},{"key":"B30","article-title":"FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion- positive solid tumors","unstructured":"Food and Drug Administration. FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion- positive solid tumors. Accessed January 24, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive"},{"key":"B31","series-title":"Cancer Metastasis Rev","first-page":"157","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan M","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D,  HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015;34:157\u2013164."},{"key":"B32","series-title":"BMC Cancer","first-page":"59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco A","year":"2004","unstructured":"Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A,  HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59."},{"key":"B33","series-title":"PLoS One","first-page":"e0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta- analysis","volume":"16","author":"Itkin B","year":"2021","unstructured":"Itkin B, Garcia A, Straminsky S,  Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta- analysis. PLoS One 2021;16:e0257976."},{"key":"B34","series-title":"Am J Cancer Res","first-page":"3266","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials","volume":"13","author":"Cai ZL","year":"2023","unstructured":"Cai ZL, Yang HT, Huang T,  Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials. Am J Cancer Res 2023;13:3266\u20133274."},{"key":"B35","series-title":"J Clin Oncol","first-page":"47","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A,  Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42:47\u201358."},{"key":"B36","series-title":"Lancet Oncol","first-page":"1261","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B,  Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 2022;23:1261\u20131273."},{"key":"B37","series-title":"Clin Cancer Res","first-page":"3573","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke ES","year":"2023","unstructured":"Duke ES, Bradford D, Marcovitz M,  FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res 2023;29:3573\u20133578."},{"key":"B38","series-title":"Br J Cancer","first-page":"1561","article-title":"Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina","volume":"110","author":"Hellman K","year":"2014","unstructured":"Hellman K, Lindquist D, Ranhem C,  Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina. Br J Cancer 2014;110:1561\u20131570."},{"key":"B39","series-title":"Am J Clin Pathol","first-page":"664","article-title":"Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1","volume":"142","author":"Feldbaum VM","year":"2014","unstructured":"Feldbaum VM, Flowers LC, Oprea-Ilies GM. Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. Am J Clin Pathol 2014;142:664\u2013669."},{"key":"B40","series-title":"Cancers (Basel)","first-page":"1046","article-title":"The role of P16, P53, KI-67 and PD-L1 immunostaining in primary vaginal cancer","volume":"15","author":"Egger EK","year":"2023","unstructured":"Egger EK, Condic M, Ralser DJ,  The role of P16, P53, KI-67 and PD-L1 immunostaining in primary vaginal cancer. Cancers (Basel) 2023;15:1046."},{"key":"B41","series-title":"Acta Obstet Gynecol Scand","first-page":"2144","article-title":"The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: a systematic review","volume":"100","author":"Rasmussen CL","year":"2021","unstructured":"Rasmussen CL, Bertoli HK, Sand FL,  The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: a systematic review. Acta Obstet Gynecol Scand 2021;100:2144\u20132156."},{"key":"B42","series-title":"Gynecol Oncol","first-page":"649","article-title":"Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes","volume":"159","author":"Kortekaas KE","year":"2020","unstructured":"Kortekaas KE, Bastiaannet E, van Doorn HC,  Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol 2020;159:649\u2013656."},{"key":"B43","series-title":"J Low Genit Tract Dis","first-page":"252","article-title":"Biomarkers p16, human papillomavirus and p53 predict recurrence and survival in early stage squamous cell carcinoma of the vulva","volume":"20","author":"Hay CM","year":"2016","unstructured":"Hay CM, Lachance JA, Lucas FL,  Biomarkers p16, human papillomavirus and p53 predict recurrence and survival in early stage squamous cell carcinoma of the vulva. J Low Genit Tract Dis 2016;20:252\u2013256."},{"key":"B44","series-title":"Anticancer Res","first-page":"1739","article-title":"P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus","volume":"25","author":"Hantschmann P","year":"2005","unstructured":"Hantschmann P, Sterzer S, Jeschke U, Friese K. P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus. Anticancer Res 2005;25:1739\u20131745."},{"key":"B45","series-title":"Gynecol Oncol","first-page":"547","article-title":"A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas","volume":"90","author":"Koyamatsu Y","year":"2003","unstructured":"Koyamatsu Y, Yokoyama M, Nakao Y,  A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. Gynecol Oncol 2003;90:547\u2013551."},{"key":"B46","series-title":"Int J Radiat Oncol Biol Phys","first-page":"746","article-title":"Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum","volume":"69","author":"Samant R","year":"2007","unstructured":"Samant R, Lau B, E C,  Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 2007;69:746\u2013750."},{"key":"B47","series-title":"Gynecol Oncol","first-page":"233","article-title":"Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract","volume":"43","author":"Roberts WS","year":"1991","unstructured":"Roberts WS, Hoffman MS, Kavanagh JJ,  Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract. Gynecol Oncol 1991;43:233\u2013236."},{"key":"B48","series-title":"Gynecol Oncol","first-page":"3","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani R","year":"2017","unstructured":"Salani R, Khanna N, Frimer M,  An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:3\u201310."},{"key":"B49","series-title":"J Am Coll Radiol","first-page":"S442","article-title":"ACR Appropriateness Criteria\u00ae Staging and Follow-up of Primary Vaginal Cancer","volume":"18","author":"Kilcoyne A","year":"2021","unstructured":"Kilcoyne A, Gottumukkala RV, Kang SK,  ACR Appropriateness Criteria\u00ae Staging and Follow-up of Primary Vaginal Cancer. J Am Coll Radiol 2021;18:S442\u2013455."},{"key":"B50","series-title":"Gynecol Oncol","first-page":"187","article-title":"Posttherapy surveillance of women with cervical cancer: an outcomes analysis","volume":"78","author":"Bodurka-Bevers D","year":"2000","unstructured":"Bodurka-Bevers D, Morris M, Eifel PJ,  Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:187\u2013193."},{"key":"B51","series-title":"Ann Oncol","first-page":"218","article-title":"Value of routine follow-up procedures for patients with stage I\/II cervical cancer treated with combined surgery-radiation therapy","volume":"15","author":"Morice P","year":"2004","unstructured":"Morice P, Deyrolle C, Rey A,  Value of routine follow-up procedures for patients with stage I\/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004;15:218\u2013223."},{"key":"B52","series-title":"Gynecol Oncol","first-page":"528","article-title":"Follow-up for women after treatment for cervical cancer: a systematic review","volume":"114","author":"Elit L","year":"2009","unstructured":"Elit L, Fyles AW, Devries MC,  Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009;114:528\u2013535."},{"key":"B53","series-title":"Gynecol Oncol","first-page":"529","article-title":"Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence","volume":"104","author":"Chung HH","year":"2007","unstructured":"Chung HH, Jo H, Kang WJ,  Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529\u2013534."},{"key":"B54","series-title":"J Clin Oncol","first-page":"967","article-title":"Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix","volume":"27","author":"Chaturvedi AK","year":"2009","unstructured":"Chaturvedi AK, Kleinerman RA, Hildesheim A,  Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009;27:967\u2013973."},{"key":"B55","series-title":"J Natl Cancer Inst","first-page":"1634","article-title":"Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk","volume":"99","author":"Chaturvedi AK","year":"2007","unstructured":"Chaturvedi AK, Engels EA, Gilbert ES,  Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634\u20131643."},{"key":"B56","series-title":"Obstet Gynecol","first-page":"319","article-title":"Radiation-associated endometrial cancer","volume":"113","author":"Kumar S","year":"2009","unstructured":"Kumar S, Shah JP, Bryant CS,  Radiation-associated endometrial cancer. Obstet Gynecol 2009;113:319\u2013325."},{"key":"B57","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1247","article-title":"Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix","volume":"55","author":"Kim JS","year":"2003","unstructured":"Kim JS, Kim JS, Kim SY,  Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2003;55:1247\u20131253."},{"key":"B58","series-title":"Gynecol Oncol","first-page":"126","article-title":"Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I\/II study","volume":"97","author":"Chung YL","year":"2005","unstructured":"Chung YL, Jian JJ, Cheng SH,  Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I\/II study. Gynecol Oncol 2005;97:126\u2013135."},{"key":"B59","series-title":"Int J Gynecol Cancer","first-page":"974","article-title":"Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers","volume":"19","author":"Marnitz S","year":"2009","unstructured":"Marnitz S, Dowdy S, Lanowska M,  Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers. Int J Gynecol Cancer 2009;19:974\u2013977."},{"key":"B60","series-title":"Gynecol Oncol","first-page":"153","article-title":"Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA","volume":"99","author":"Berek JS","year":"2005","unstructured":"Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005;99:153\u2013159."},{"key":"B61","series-title":"Gynecol Oncol","first-page":"261","article-title":"Total pelvic exenteration: the Albert Einstein College of Medicine\/Montefiore Medical Center Experience (1987 to 2003)","volume":"101","author":"Goldberg GL","year":"2006","unstructured":"Goldberg GL, Sukumvanich P, Einstein MH,  Total pelvic exenteration: the Albert Einstein College of Medicine\/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 2006;101:261\u2013268."},{"key":"B62","series-title":"Obstet Gynecol","first-page":"934","article-title":"Pelvic exenteration, University of Michigan: 100 patients at 5 years","volume":"74","author":"Morley GW","year":"1989","unstructured":"Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989;74:934\u2013943."},{"key":"B63","series-title":"J Surg Oncol","first-page":"476","article-title":"Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers","volume":"95","author":"Fleisch MC","year":"2007","unstructured":"Fleisch MC, Pantke P, Beckmann MW,  Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 2007;95:476\u2013484."},{"key":"B64","series-title":"Int J Radiat Oncol Biol Phys","first-page":"504","article-title":"Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies","volume":"69","author":"Tran PT","year":"2007","unstructured":"Tran PT, Su Z, Hara W,  Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2007;69:504\u2013511."},{"key":"B65","series-title":"Am J Obstet Gynecol","first-page":"881","article-title":"Pelvic exenteration: analysis of 296 patients","volume":"129","author":"Rutledge FN","year":"1977","unstructured":"Rutledge FN, Smith JP, Wharton JT, O\u2019Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977;129:881\u2013892."},{"key":"B66","series-title":"Am J Obstet Gynecol","first-page":"907","article-title":"Exenterative operations: experience with 198 patients","volume":"121","author":"Symmonds RE","year":"1975","unstructured":"Symmonds RE, Pratt JH, Webb MJ. Exenterative operations: experience with 198 patients. Am J Obstet Gynecol 1975;121:907\u2013918."},{"key":"B67","series-title":"Int J Gynecol Cancer","first-page":"298","article-title":"Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity","volume":"17","author":"Soper JT","year":"2007","unstructured":"Soper JT, Secord AA, Havrilesky LJ,  Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity. Int J Gynecol Cancer 2007;17:298\u2013303."},{"key":"B68","series-title":"Gynecol Oncol","first-page":"39","article-title":"Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques","volume":"87","author":"Mirhashemi R","year":"2002","unstructured":"Mirhashemi R, Averette HE, Lambrou N,  Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques. Gynecol Oncol 2002;87:39\u201345."},{"key":"B69","series-title":"J Surg Oncol","first-page":"224","article-title":"Psychosocial issues: pelvic exenterative surgery","volume":"76","author":"Turns D.","year":"2001","unstructured":"Turns D. Psychosocial issues: pelvic exenterative surgery. J Surg Oncol 2001;76:224\u2013236."},{"key":"B70","series-title":"Radiat Oncol","first-page":"77","article-title":"Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients","volume":"10","author":"Im JH","year":"2015","unstructured":"Im JH, Yoon HI, Kim S,  Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients. Radiat Oncol 2015;10:77."},{"key":"B71","series-title":"Int J Gynecol Cancer","first-page":"1214","article-title":"Loop electrosurgical excision procedure findings for identification of patients with early-stage cervical cancer suitable for less radical surgery","volume":"22","author":"Kim MK","year":"2012","unstructured":"Kim MK, Kim MA, Kim JW,  Loop electrosurgical excision procedure findings for identification of patients with early-stage cervical cancer suitable for less radical surgery. Int J Gynecol Cancer 2012;22:1214\u20131219."},{"key":"B72","series-title":"J Palliat Med","first-page":"438","article-title":"Top ten tips palliative care clinicians should know about caring for patients with cervical cancer","volume":"24","author":"Hoppenot C","year":"2021","unstructured":"Hoppenot C, Littell RD, DeEulis T, Hartenbach EM. Top ten tips palliative care clinicians should know about caring for patients with cervical cancer. J Palliat Med 2021;24:438\u2013442."},{"key":"B73","series-title":"Best Pract Res Clin Obstet Gynaecol","first-page":"265","article-title":"Palliative radiation therapy for gynaecological malignancies","volume":"15","author":"Smith SC","year":"2001","unstructured":"Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol 2001;15:265\u2013278."},{"key":"B74","series-title":"Int J Radiat Oncol Biol Phys","first-page":"399","article-title":"Effect of rest interval on tumor and normal tissue response\u2013a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502)","volume":"25","author":"Spanos WJ","year":"1993","unstructured":"Spanos WJ, Perez CA, Marcus S,  Effect of rest interval on tumor and normal tissue response\u2013a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys 1993;25:399\u2013403."},{"key":"B75","series-title":"Cancer","first-page":"1462","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz ST","year":"2007","unstructured":"Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2007;109:1462\u20131470."},{"key":"B76","series-title":"J Clin Oncol","first-page":"2804","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Rose PG","year":"2007","unstructured":"Rose PG, Ali S, Watkins E,  Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2804\u20132810."},{"key":"B77","series-title":"Gynecol Oncol","first-page":"27","article-title":"Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence","volume":"93","author":"Viswanathan AN","year":"2004","unstructured":"Viswanathan AN, Deavers MT, Jhingran A,  Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004;93:27\u201333."},{"key":"B78","series-title":"Am J Obstet Gynecol","first-page":"503.e1","article-title":"Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial","volume":"197","author":"Stehman FB","year":"2007","unstructured":"Stehman FB, Ali S, Keys HM,  Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 2007;197:503.e1\u20136."},{"key":"B79","series-title":"Oncologist","first-page":"843","article-title":"Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks","volume":"18","author":"Nam EJ","year":"2013","unstructured":"Nam EJ, Lee M, Yim GW,  Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013;18:843\u2013849."},{"key":"B80","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1226","article-title":"Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial","volume":"55","author":"Lorvidhaya V","year":"2003","unstructured":"Lorvidhaya V, Chitapanarux I, Sangruchi S,  Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226\u20131232."},{"key":"B81","series-title":"Gynecol Oncol","first-page":"404","article-title":"Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma","volume":"81","author":"Pattaranutaporn P","year":"2001","unstructured":"Pattaranutaporn P, Thirapakawong C, Chansilpa Y,  Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001;81:404\u2013407."},{"key":"B82","series-title":"Radiat Oncol","first-page":"15","article-title":"Radiosensitizers in cervical cancer. Cisplatin and beyond","volume":"1","author":"Candelaria M","year":"2006","unstructured":"Candelaria M, Garcia-Arias A, Cetina L, Due\u00f1as-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15."},{"key":"B83","series-title":"Radiother Oncol","first-page":"181","article-title":"Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer","volume":"37","author":"Christie DR","year":"1995","unstructured":"Christie DR, Bull CA, Gebski V, Langlands AO. Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Radiother Oncol 1995;37:181\u2013189."},{"key":"B84","series-title":"Int J Radiat Oncol Biol Phys","first-page":"979","article-title":"Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix","volume":"38","author":"Rakovitch E","year":"1997","unstructured":"Rakovitch E, Fyles AW, Pintilie M, Leung PM. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:979\u2013987."},{"key":"B85","series-title":"J Gynecol Oncol","first-page":"221","article-title":"Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study","volume":"20","author":"Verma AK","year":"2009","unstructured":"Verma AK, Arya AK, Kumar M,  Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study. J Gynecol Oncol 2009;20:221\u2013226."},{"key":"B86","series-title":"Eur J Gynaecol Oncol","first-page":"115","article-title":"Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose","volume":"23","author":"Cerrotta A","year":"2002","unstructured":"Cerrotta A, Gardan G, Cavina R,  Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002;23:115\u2013119."},{"key":"B87","series-title":"J Clin Oncol","first-page":"5802","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802\u20135812."},{"key":"B88","series-title":"Clin Oncol (R Coll Radiol)","first-page":"38","article-title":"Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects","volume":"18","author":"King M","year":"2006","unstructured":"King M, McConkey C, Latief TN,  Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 2006;18:38\u201345."},{"key":"B89","series-title":"Clin Oncol (R Coll Radiol)","first-page":"358","article-title":"Long-term survival and late toxicity after chemoradiotherapy for cervical cancer\u2013the Addenbrooke's experience","volume":"20","author":"Tan LT","year":"2008","unstructured":"Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer\u2013the Addenbrooke's experience. Clin Oncol (R Coll Radiol) 2008;20:358\u2013364."},{"key":"B90","series-title":"J Clin Oncol","first-page":"5505","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk BJ","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS,  First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol 2023;41:5505\u20135511."},{"key":"B91","series-title":"Lancet","first-page":"1654","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari KS","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT,  Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654\u20131663."},{"key":"B92","series-title":"Lancet Oncol","first-page":"301","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson RT","year":"2015","unstructured":"Penson RT, Huang HQ, Wenzel LB,  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16:301\u2013311."},{"key":"B93","series-title":"Int J Gynecol Cancer","first-page":"1237","article-title":"Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer","volume":"27","author":"Rosen VM","year":"2017","unstructured":"Rosen VM, Guerra I, McCormack M,  Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 2017;27:1237\u20131246."},{"key":"B94","series-title":"J Clin Oncol","first-page":"2129","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa R","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T,  Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:2129\u20132135."},{"key":"B95","series-title":"Gynecol Oncol","first-page":"299","article-title":"A comparison of cisplatin\/paclitaxel and carboplatin\/paclitaxel in stage IVB, recurrent or persistent cervical cancer","volume":"105","author":"Moore KN","year":"2007","unstructured":"Moore KN, Herzog TJ, Lewin S,  A comparison of cisplatin\/paclitaxel and carboplatin\/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105:299\u2013303."},{"key":"B96","series-title":"Gynecol Oncol","first-page":"117","article-title":"A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer","volume":"133","author":"Lorusso D","year":"2014","unstructured":"Lorusso D, Petrelli F, Coinu A,  A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 2014;133:117\u2013123."},{"key":"B97","series-title":"Cancer","first-page":"899","article-title":"Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"48","author":"Thigpen T","year":"1981","unstructured":"Thigpen T, Shingleton H, Homesley H,  Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899\u2013903."},{"key":"B98","series-title":"Gynecol Oncol","first-page":"198","article-title":"A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"32","author":"Thigpen JT","year":"1989","unstructured":"Thigpen JT, Blessing JA, DiSaia PJ,  A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198\u2013202."},{"key":"B99","series-title":"Cancer Treat Rev","first-page":"603","article-title":"Chemotherapy for recurrent cervical cancer","volume":"34","author":"Pectasides D","year":"2008","unstructured":"Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008;34:603\u2013613."},{"key":"B100","series-title":"J Clin Oncol","first-page":"3113","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore DH","year":"2004","unstructured":"Moore DH, Blessing JA, McQuellon RP,  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113\u20133119."},{"key":"B101","series-title":"J Clin Oncol","first-page":"1462","article-title":"A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"7","author":"McGuire WP","year":"1989","unstructured":"McGuire WP, Arseneau J, Blessing JA,  A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462\u20131468."},{"key":"B102","series-title":"Gynecol Oncol","first-page":"332","article-title":"A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study","volume":"39","author":"Weiss GR","year":"1990","unstructured":"Weiss GR, Green S, Hannigan EV,  A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990;39:332\u2013336."},{"key":"B103","series-title":"Anticancer Drugs","first-page":"657","article-title":"An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix","volume":"8","author":"Kudelka AP","year":"1997","unstructured":"Kudelka AP, Winn R, Edwards CL,  An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997;8:657\u2013661."},{"key":"B104","series-title":"J Clin Oncol","first-page":"792","article-title":"Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study","volume":"14","author":"McGuire WP","year":"1996","unstructured":"McGuire WP, Blessing JA, Moore D,  Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996;14:792\u2013795."},{"key":"B105","series-title":"Gynecol Oncol","first-page":"54","article-title":"Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience","volume":"98","author":"Tinker AV","year":"2005","unstructured":"Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 2005;98:54\u201358."},{"key":"B106","series-title":"J Clin Oncol","first-page":"4626","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long HJ","year":"2005","unstructured":"Long HJ, Bundy BN, Grendys EC,  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626\u20134633."},{"key":"B107","series-title":"J Natl Compr Canc Netw","first-page":"53","article-title":"Chemotherapy for advanced, recurrent, and metastatic cervical cancer","volume":"6","author":"Moore DH.","year":"2008","unstructured":"Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008;6:53\u201357."},{"key":"B108","series-title":"Gynecol Oncol","first-page":"S67","article-title":"Chemotherapy for recurrent and metastatic cervical cancer","volume":"110","author":"Tao X","year":"2008","unstructured":"Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008;110:S67\u201371."},{"key":"B109","series-title":"J Clin Oncol","first-page":"4649","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk BJ","year":"2009","unstructured":"Monk BJ, Sill MW, McMeekin DS,  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649\u20134655."},{"key":"B110","series-title":"Gynecol Oncol","first-page":"64","article-title":"Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer","volume":"130","author":"Zighelboim I","year":"2013","unstructured":"Zighelboim I, Wright JD, Gao F,  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130:64\u201368."},{"key":"B111","series-title":"J Clin Oncol","first-page":"4035","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel JS","year":"2017","unstructured":"Frenel JS, Le Tourneau C, O\u2019Neil B,  Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 2017;35:4035\u20134041."},{"key":"B112","series-title":"Ann Oncol","first-page":"929","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio M","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L,  Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929\u2013938."},{"key":"B113","article-title":"FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection","unstructured":"Food and Drug Administration. FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection. Accessed November 10, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection"},{"key":"B114","series-title":"Gynecol Oncol","first-page":"451","article-title":"Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study","volume":"127","author":"Alberts DS","year":"2012","unstructured":"Alberts DS, Blessing JA, Landrum LM,  Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 2012;127:451\u2013455."},{"key":"B115","series-title":"Am J Clin Oncol","first-page":"428","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"30","author":"Garcia AA","year":"2007","unstructured":"Garcia AA, Blessing JA, Vaccarello L,  Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;30:428\u2013431."},{"key":"B116","series-title":"Am J Clin Oncol","first-page":"439","article-title":"A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"19","author":"Look KY","year":"1996","unstructured":"Look KY, Blessing JA, Gallup DG, Lentz SS. A phase II trial of 5- fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1996;19:439\u2013441."},{"key":"B117","series-title":"Gynecol Oncol","first-page":"103","article-title":"Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"96","author":"Schilder RJ","year":"2005","unstructured":"Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2005;96:103\u2013107."},{"key":"B118","series-title":"Cancer Chemother Pharmacol","first-page":"280","article-title":"A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix","volume":"18","author":"Coleman RE","year":"1986","unstructured":"Coleman RE, Harper PG, Gallagher C,  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986;18:280\u2013283."},{"key":"B119","series-title":"Am J Obstet Gynecol","first-page":"805","article-title":"Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study","volume":"168","author":"Sutton GP","year":"1993","unstructured":"Sutton GP, Blessing JA, McGuire WP,  Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993;168:805\u2013807."},{"key":"B120","series-title":"J Clin Oncol","first-page":"625","article-title":"Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix","volume":"15","author":"Verschraegen CF","year":"1997","unstructured":"Verschraegen CF, Levy T, Kudelka AP,  Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625\u2013631."},{"key":"B121","series-title":"Eur J Cancer","first-page":"1624","article-title":"Phase II study of mitomycin- C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study","volume":"37","author":"Wagenaar HC","year":"2001","unstructured":"Wagenaar HC, Pecorelli S, Mangioni C,  Phase II study of mitomycin- C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer 2001;37:1624\u20131628."},{"key":"B122","series-title":"Gynecol Oncol","first-page":"65","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller DS","year":"2008","unstructured":"Miller DS, Blessing JA, Bodurka DC,  Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110:65\u201370."},{"key":"B123","series-title":"Gynecol Oncol","first-page":"446","article-title":"Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"77","author":"Bookman MA","year":"2000","unstructured":"Bookman MA, Blessing JA, Hanjani P,  Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446\u2013449."},{"key":"B124","series-title":"Gynecol Oncol","first-page":"213","article-title":"A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"81","author":"Muderspach LI","year":"2001","unstructured":"Muderspach LI, Blessing JA, Levenback C, Moore JL. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001;81:213\u2013215."},{"key":"B125","series-title":"Gynecol Oncol","first-page":"108","article-title":"Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"96","author":"Muggia FM","year":"2005","unstructured":"Muggia FM, Blessing JA, Waggoner S,  Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:108\u2013111."},{"key":"B126","series-title":"Lancet Oncol","first-page":"609","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman RL","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C,  Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:609\u2013619."},{"key":"B127","series-title":"Drugs","first-page":"2141","article-title":"Tisotumab vedotin: first Approval","volume":"81","author":"Markham A.","year":"2021","unstructured":"Markham A. Tisotumab vedotin: first Approval. Drugs 2021;81:2141\u20132147."},{"key":"B128","series-title":"N Engl J Med","first-page":"44","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote I","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K,  Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 2024;391:44\u201355."},{"key":"B129","series-title":"N Engl J Med","first-page":"544","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari KS","year":"2022","unstructured":"Tewari KS, Monk BJ, Vergote I,  Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544\u2013555."},{"key":"B130","series-title":"Eur J Cancer","first-page":"299","article-title":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","volume":"174","author":"Oaknin A","year":"2022","unstructured":"Oaknin A, Monk BJ, Vergote I,  EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer 2022;174:299\u2013309."},{"key":"B131","series-title":"Lancet Oncol","first-page":"588","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial","volume":"25","author":"Oaknin A","year":"2024","unstructured":"Oaknin A, Moore K, Meyer T,  Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Lancet Oncol 2024;25:588\u2013602."},{"key":"B132","article-title":"FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection","unstructured":"Food and Drug Administration. FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection. Accessed January 24, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection"},{"key":"B133","series-title":"Oncology (Williston Park)","first-page":"1166","article-title":"ACR Appropriateness Criteria management of vaginal cancer","volume":"27","author":"Lee LJ","year":"2013","unstructured":"Lee LJ, Jhingran A, Kidd E,  ACR Appropriateness Criteria management of vaginal cancer. Oncology (Williston Park) 2013;27:1166\u20131173."},{"key":"B134","series-title":"Front Oncol","first-page":"34","article-title":"The role of PET\/CT in cervical cancer","volume":"3","author":"Herrera FG","year":"2013","unstructured":"Herrera FG, Prior JO. The role of PET\/CT in cervical cancer. Front Oncol 2013;3:34."},{"key":"B135","series-title":"Int J Radiat Oncol Biol Phys","first-page":"138","article-title":"Definitive radiation therapy for squamous cell carcinoma of the vagina","volume":"62","author":"Frank SJ","year":"2005","unstructured":"Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005;62:138\u2013147."},{"key":"B136","series-title":"Gynecol Oncol","first-page":"404","article-title":"Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology","volume":"120","author":"Higginson DS","year":"2011","unstructured":"Higginson DS, Morris DE, Jones EL,  Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol Oncol 2011;120:404\u2013412."},{"key":"B137","series-title":"Int J Radiat Oncol Biol Phys","first-page":"147","article-title":"Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer","volume":"74","author":"Choi CW","year":"2009","unstructured":"Choi CW, Cho CK, Yoo SY,  Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009;74:147\u2013153."},{"key":"B138","series-title":"Radiother Oncol","first-page":"36","article-title":"Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer","volume":"145","author":"Schmid MP","year":"2020","unstructured":"Schmid MP, Fokdal L, Westerveld H,  Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: target concept for image guided adaptive brachytherapy in primary vaginal cancer. Radiother Oncol 2020;145:36\u201344."},{"key":"B139","series-title":"Int J Radiat Oncol Biol Phys","first-page":"654","article-title":"GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina","volume":"115","author":"Kamrava M","year":"2023","unstructured":"Kamrava M, Leung E, Bachand F,  GEC-ESTRO (ACROP)-ABS-CBG consensus brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina. Int J Radiat Oncol Biol Phys 2023;115:654\u2013663."},{"key":"B140","series-title":"Lancet Oncol","first-page":"538","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"Potter R","year":"2021","unstructured":"Potter R, Tanderup K, Schmid MP,  MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021;22:538\u2013547."},{"key":"B141","series-title":"Radiother Oncol","first-page":"24","article-title":"Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study","volume":"157","author":"Petric P","year":"2021","unstructured":"Petric P, Lindegaard JC, Sturdza A,  Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. Radiother Oncol 2021;157:24\u201331."},{"key":"B142","series-title":"Radiother Oncol","first-page":"116","article-title":"Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"Potter R","year":"2011","unstructured":"Potter R, Georg P, Dimopoulos JC,  Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 2011;100:116\u2013123."},{"key":"B143","series-title":"Radiother Oncol","first-page":"235","article-title":"Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-Meder C","year":"2005","unstructured":"Haie-Meder C, Potter R, Van Limbergen E,  Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005;74:235\u2013245."},{"key":"B144","series-title":"Int J Radiat Oncol Biol Phys","first-page":"788","article-title":"Assessment of parametrial response by growth pattern in patients with International Federation of Gynecology and Obstetrics stage IIB and IIIB cervical cancer: analysis of patients from a prospective, multicenter trial (EMBRACE)","volume":"93","author":"Yoshida K","year":"2015","unstructured":"Yoshida K, Jastaniyah N, Sturdza A,  Assessment of parametrial response by growth pattern in patients with International Federation of Gynecology and Obstetrics stage IIB and IIIB cervical cancer: analysis of patients from a prospective, multicenter trial (EMBRACE). Int J Radiat Oncol Biol Phys 2015;93:788\u2013796."},{"key":"B145","series-title":"Int J Radiat Oncol Biol Phys","first-page":"104","article-title":"Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society","volume":"76","author":"Viswanathan AN","year":"2010","unstructured":"Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2010;76:104\u2013109."},{"key":"B146","series-title":"Pract Radiat Oncol","first-page":"173","article-title":"An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: a single institution experience","volume":"1","author":"Hallock A","year":"2011","unstructured":"Hallock A, Surry K, Batchelar D,  An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: a single institution experience. Pract Radiat Oncol 2011;1:173\u2013181."},{"key":"B147","series-title":"Gynecol Oncol","first-page":"501","article-title":"Brachytherapy improves survival in primary vaginal cancer","volume":"141","author":"Orton A","year":"2016","unstructured":"Orton A, Boothe D, Williams N,  Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol 2016;141:501\u2013506."},{"key":"B148","series-title":"Acta Obstet Gynecol Scand","first-page":"355","article-title":"Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy","volume":"80","author":"Kucera H","year":"2001","unstructured":"Kucera H, Mock U, Knocke TH,  Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. Acta Obstet Gynecol Scand 2001;80:355\u2013360."},{"key":"B149","series-title":"Int J Radiat Oncol Biol Phys","first-page":"639","article-title":"Dosimetric considerations in irradiation of carcinoma of the vagina","volume":"2","author":"Perez CA","year":"1977","unstructured":"Perez CA, Korba A, Sharma S. Dosimetric considerations in irradiation of carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1977;2:639\u2013649."},{"key":"B150","series-title":"Brachytherapy","first-page":"68","article-title":"American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer","volume":"11","author":"Beriwal S","year":"2012","unstructured":"Beriwal S, Demanes DJ, Erickson B,  American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. Brachytherapy 2012;11:68\u201375."},{"key":"B151","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1880","article-title":"Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results","volume":"82","author":"Dimopoulos JC","year":"2012","unstructured":"Dimopoulos JC, Schmid MP, Fidarova E,  Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 2012;82:1880\u20131888."},{"key":"B152","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1108","article-title":"Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series","volume":"62","author":"Ferrigno R","year":"2005","unstructured":"Ferrigno R, Nishimoto IN, Novaes PE,  Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series. Int J Radiat Oncol Biol Phys 2005;62:1108\u20131116."},{"key":"B153","series-title":"Clin Transl Radiat Oncol","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"Potter R","year":"2018","unstructured":"Potter R, Tanderup K, Kirisits C,  The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018;9:48\u201360."},{"key":"B154","series-title":"Gynecol Oncol","first-page":"456","article-title":"Management and outcomes of primary vaginal cancer","volume":"159","author":"Yang J","year":"2020","unstructured":"Yang J, Delara R, Magrina J,  Management and outcomes of primary vaginal cancer. Gynecol Oncol 2020;159:456\u2013463."},{"key":"B155","series-title":"Int J Radiat Oncol Biol Phys","first-page":"348","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer","volume":"79","author":"Lim K","year":"2011","unstructured":"Lim K, Small W, Portelance L,  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2011;79:348\u2013355."},{"key":"B156","series-title":"J Natl Compr Canc Netw","first-page":"1425","article-title":"The emerging use of IMRT for treatment of cervical cancer","volume":"8","author":"Loiselle C","year":"2010","unstructured":"Loiselle C, Koh WJ. The emerging use of IMRT for treatment of cervical cancer. J Natl Compr Canc Netw 2010;8:1425\u20131434."},{"key":"B157","series-title":"Int J Radiat Oncol Biol Phys","first-page":"166","article-title":"Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer","volume":"68","author":"Beriwal S","year":"2007","unstructured":"Beriwal S, Gan GN, Heron DE,  Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2007;68:166\u2013171."},{"key":"B158","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1438","article-title":"Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy","volume":"67","author":"Chen MF","year":"2007","unstructured":"Chen MF, Tseng CJ, Tseng CC,  Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1438\u20131444."},{"key":"B159","series-title":"Cancer J","first-page":"200","article-title":"Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients","volume":"14","author":"Chen MF","year":"2008","unstructured":"Chen MF, Tseng CJ, Tseng CC,  Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients. Cancer J 2008;14:200\u2013206."},{"key":"B160","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1170","article-title":"Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies","volume":"65","author":"Salama JK","year":"2006","unstructured":"Salama JK, Mundt AJ, Roeske J, Mehta N. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65:1170\u20131176."},{"key":"B161","series-title":"Int J Radiat Oncol Biol Phys","first-page":"428","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer","volume":"71","author":"Small W","year":"2008","unstructured":"Small W, Mell LK, Anderson P,  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:428\u2013434."},{"key":"B162","series-title":"Eur J Gynaecol Oncol","first-page":"62","article-title":"Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study","volume":"35","author":"Erpolat OP","year":"2014","unstructured":"Erpolat OP, Alco G, Caglar HB,  Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. Eur J Gynaecol Oncol 2014;35:62\u201366."},{"key":"B163","series-title":"Int J Radiat Oncol Biol Phys","first-page":"357","article-title":"Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer","volume":"88","author":"Verma J","year":"2014","unstructured":"Verma J, Sulman EP, Jhingran A,  Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 2014;88:357\u2013362."},{"key":"B164","series-title":"Int J Radiat Oncol Biol Phys","first-page":"536","article-title":"Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2)","volume":"97","author":"Mell LK","year":"2017","unstructured":"Mell LK, Sirak I, Wei L,  Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys 2017;97:536\u2013545."},{"key":"B165","series-title":"Radiother Oncol","first-page":"273","article-title":"The effect of treatment duration in the local control of cervix cancer","volume":"25","author":"Fyles A","year":"1992","unstructured":"Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25:273\u2013279."},{"key":"B166","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1051","article-title":"Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome","volume":"27","author":"Girinsky T","year":"1993","unstructured":"Girinsky T, Rey A, Roche B,  Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051\u20131056."},{"key":"B167","series-title":"Int J Radiat Oncol Biol Phys","first-page":"391","article-title":"The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study","volume":"25","author":"Lanciano RM","year":"1993","unstructured":"Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391\u2013397."},{"key":"B168","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1275","article-title":"Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy","volume":"32","author":"Perez CA","year":"1995","unstructured":"Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275\u20131288."},{"key":"B169","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1301","article-title":"The adverse effect of treatment prolongation in cervical carcinoma","volume":"32","author":"Petereit DG","year":"1995","unstructured":"Petereit DG, Sarkaria JN, Chappell R,  The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301\u20131307."},{"key":"B170","series-title":"Front Oncol","first-page":"943703","article-title":"Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: a single institution experience","volume":"12","author":"Ren X","year":"2022","unstructured":"Ren X, Fu Y, Liu Z,  Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: a single institution experience. Front Oncol 2022;12:943703."},{"key":"B171","series-title":"Clin Oncol (R Coll Radiol)","first-page":"682","article-title":"Stereotactic body reirradiation in gynaecological cancer: outcomes and toxicities from a single institution experience","volume":"35","author":"Macchia G","year":"2023","unstructured":"Macchia G, Pezzulla D, Cilla S,  Stereotactic body reirradiation in gynaecological cancer: outcomes and toxicities from a single institution experience. Clin Oncol (R Coll Radiol) 2023;35:682\u2013693."},{"key":"B172","series-title":"Gynecol Oncol","first-page":"208","article-title":"Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer","volume":"151","author":"Kim HJ","year":"2018","unstructured":"Kim HJ, Chang JS, Koom WS,  Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. Gynecol Oncol 2018;151:208\u2013214."},{"key":"B173","series-title":"PLoS One","first-page":"e65048","article-title":"Concurrent chemoradiation for vaginal cancer","volume":"8","author":"Miyamoto DT","year":"2013","unstructured":"Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. PLoS One 2013;8:e65048."},{"key":"B174","series-title":"Gynecol Oncol","first-page":"495","article-title":"Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study","volume":"135","author":"Rajagopalan MS","year":"2014","unstructured":"Rajagopalan MS, Xu KM, Lin JF,  Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol 2014;135:495\u2013502."},{"key":"B175","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1304","article-title":"Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients","volume":"73","author":"Wo JY","year":"2009","unstructured":"Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009;73:1304\u20131312."},{"key":"B176","series-title":"Int J Gynecol Cancer","first-page":"584","article-title":"Laparoscopic ovarian transposition in patients with early cervical cancer","volume":"18","author":"Pahisa J","year":"2008","unstructured":"Pahisa J, Martinez-Roman S, Martinez-Zamora MA,  Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer 2008;18:584\u2013589."},{"key":"B177","series-title":"Fertil Steril","first-page":"743","article-title":"Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination","volume":"74","author":"Morice P","year":"2000","unstructured":"Morice P, Juncker L, Rey A,  Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril 2000;74:743\u2013748."},{"key":"B178","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1289","article-title":"Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix","volume":"32","author":"Eifel PJ","year":"1995","unstructured":"Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995;32:1289\u20131300."},{"key":"B179","series-title":"Int J Gynecol Cancer","first-page":"1074","article-title":"Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix","volume":"20","author":"Forrest JL","year":"2010","unstructured":"Forrest JL, Ackerman I, Barbera L,  Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix. Int J Gynecol Cancer 2010;20:1074\u20131078."},{"key":"B180","first-page":"325","article-title":"Biologic and physical aspects of radiation oncology","author":"Erickson-Whitmann B","year":"2009","unstructured":"Erickson-Whitmann B, Rownd J, Khater K. Biologic and physical aspects of radiation oncology. In: Barakat R, Markman M, Randall M, eds. Principles and Practice of Gynecology Oncology, 5th Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:325\u2013380."},{"key":"B181","series-title":"Int J Radiat Oncol Biol Phys","first-page":"855","article-title":"Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation","volume":"44","author":"Perez CA","year":"1999","unstructured":"Perez CA, Grigsby PW, Lockett MA,  Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys 1999;44:855\u2013866."},{"key":"B182","series-title":"J Allergy Clin Immunol","first-page":"574","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells MC","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE,  Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574\u2013580."},{"key":"B183","series-title":"Ann Emerg Med","first-page":"373","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson HA","year":"2006","unstructured":"Sampson HA, Munoz-Furlong A, Campbell RL,  Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373\u2013380."},{"key":"B184","series-title":"Int J Emerg Med","first-page":"3","article-title":"Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis","volume":"2","author":"Manivannan V","year":"2009","unstructured":"Manivannan V, Decker WW, Stead LG,  Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:3\u20135."},{"key":"B185","series-title":"Oncologist","first-page":"601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz HJ.","year":"2007","unstructured":"Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601\u2013609."},{"key":"B186","series-title":"J Clin Oncol","first-page":"4611","article-title":"Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity","volume":"21","author":"Markman M","year":"2003","unstructured":"Markman M, Zanotti K, Peterson G,  Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:4611\u20134614."},{"key":"B187","series-title":"Gynecol Oncol","first-page":"393","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee CW","year":"2005","unstructured":"Lee CW, Matulonis UA, Castells MC. Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393\u2013399."},{"key":"B188","series-title":"Gynecol Oncol","first-page":"370","article-title":"Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions","volume":"95","author":"Lee CW","year":"2004","unstructured":"Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions. Gynecol Oncol 2004;95:370\u2013376."},{"key":"B189","series-title":"J Clin Virol","first-page":"189","article-title":"Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening","volume":"38","author":"Arbyn M","year":"2007","unstructured":"Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38:189\u2013197."},{"key":"B190","series-title":"CMAJ","first-page":"469","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials","volume":"177","author":"Rambout L","year":"2007","unstructured":"Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469\u2013479."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-p101.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-p101.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-p101.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:34Z","timestamp":1773318694000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-p101.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":380,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0011","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}